دورية أكاديمية
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial
| العنوان: | Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial |
|---|---|
| المؤلفون: | Richardson, Paul G., Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell, Karlin, Lionel, Benboubker, Lotfi, Voog, Eric, Yoon, Sung-Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Villarreal, Miguel, Twumasi-Ankrah, Philip, Labotka, Richard, Rifkin, Robert M., Lonial, Sagar, Kumar, Shaji K., Rajkumar, S. Vincent, Moreau, Philippe |
| المصدر: | EJHAEM ; ISSN: 2688-6146 |
| سنة النشر: | 2023 |
| المجموعة: | Ghent University Academic Bibliography |
| مصطلحات موضوعية: | Medicine and Health Sciences, depth of response, ixazomib, multiple myeloma, response kinetics, LENALIDOMIDE, SURVIVAL, KINETICS, THERAPY |
| الوصف: | Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0-4 months; n = 424) versus late responders (best confirmed response >4 months; n = 281). Newly diagnosed patients enrolled in TOURMALINE-MM2 receiving ixazomib-lenalidomide-dexamethasone (IRd) (n = 351) or placebo-Rd (n = 354) were evaluated post hoc. Deeper responses were associated with longer PFS (complete response [CR] not reached [NR], very good partial response [VGPR] 37.2 months, partial response [PR] 16.4 months) and DOR (CR NR, VGPR 42.6 months, PR 15.4 months). Among patients with a PFS (n = 511) or DOR (n = 484) of >= 6 months who achieved >= PR, median PFS was prolonged among late versus early responders receiving IRd (59.7 vs. 17.9 months) or placebo-Rd (56.6 vs. 12.4 months), as was median DOR (IRd, NR vs. 20.9 months; placebo-Rd, 58.2 vs. 11.7 months). While the treatment paradigm for newly diagnosed MM is treatment to progression, our findings suggest slowness of response to a proteasome inhibitor-immunomodulatory drug-steroid combination is not a negative predictor of outcome. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMRTest; http://hdl.handle.net/1854/LU-01HYZTXAMK5TTTJXXA7WKKQEMRTest; http://doi.org/10.1002/jha2.759Test; https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMR/file/01HYZTXHV49EQCFMJN7H2WFH32Test |
| DOI: | 10.1002/jha2.759 |
| الإتاحة: | https://doi.org/10.1002/jha2.759Test https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMRTest http://hdl.handle.net/1854/LU-01HYZTXAMK5TTTJXXA7WKKQEMRTest https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMR/file/01HYZTXHV49EQCFMJN7H2WFH32Test |
| حقوق: | Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F042ECCE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/jha2.759 |
|---|